Equine IL-6 Biotinylated Antibody Summary
Phe26-Met208
Accession # Q95181
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-6
Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is central to the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature equine IL-6 is 181 amino acids (aa) in length and shares 61%, 42%, and 43% aa sequence identity with human, mouse, and rat IL-6 (5). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL‑6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 8).
- Van Snick, J. (1990) Annu. Rev. Immunol. 8:253.
- Hodge, D.R. et al. (2005) Eur. J. Cancer 41:2502.
- Jones, S.A. (2005) J. Immunol. 175:3468.
- Rose-John, S. et al. (2006) J. Leukoc. Biol. 80:227.
- Swiderski, S.E. et al. Vet. Immunol. Immunopathol. 77:213.
- Murakami, M. et al. (1993) Science 260:1808.
- Muller-Newen, G. (2003) Sci. STKE 2003:PE40.
- Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.
Product Datasheets
Citations for Equine IL-6 Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
2
Citations: Showing 1 - 2
Filter your results:
Filter by:
-
Serum Health Biomarkers in African and Asian Elephants: Value Ranges and Clinical Values Indicative of the Immune Response
Authors: Katie L. Edwards, Michele A. Miller, Jessica Siegal-Willott, Janine L. Brown
Animals (Basel)
-
Serum interleukin-6 (IL-6) and IL-10 concentrations in normal and septic neonatal foals.
Authors: Burton AB, Wagner B, Erb HN, Ainsworth DM
Vet. Immunol. Immunopathol., 2009-05-18;132(2):122-8.
Species: Equine
Sample Types: Colostrum, Serum
Applications: ELISA Detection
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Equine IL-6 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Equine IL-6 Biotinylated Antibody and earn rewards!
Have you used Equine IL-6 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image